Reacta Biotech

IMPROVING THE QUALITY OF LIFE FOR SEVERE FOOD ALLERGY SUFFERERS

EXPERIENCE TO DELIVER RESULTS 

  • World leading scientific and clinical experts in food allergy

  • Business already generating significant revenue through services to clinical trials space

  • Proven scale up capabilities

  • Relocated to a large world-class manufacturing facility of Pharma standard, previously MHRA licensed

  • IP strategy in place with 2 patents in advanced stages

TRACTION & FOCUSED STRATEGY

  • Existing client base for Phase II Clinical Trials

  • Opportunity to expand into other allergens

  • Pharma GMP will expand access to Phase III trials & German Market

  • Defined path to achieve product licensing (Marketing Authorisation/”MA”)

  • Pharma GMP & MA achievable within 24 months

  • No additional clinical trials required for current product

REVENUE GENERATING WITH HIGH NEAR-TERM GROWTH & VALUE

  • Our target markets have unmet needs

  • Addressable market opportunity of US$18bn in US & Europe

  • Potential exit in 2021 at market proven valuations

Global food allergy cases have risen substantially since the 1990’s, with a 600% rise in hospitalisations due to anaphylaxis.